Difference between revisions of "Team:ETH Zurich"
| Line 27: | Line 27: | ||
<h1>WHY</h1> | <h1>WHY</h1> | ||
<p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p> | <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p> | ||
| − | <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented <span title="Came close to being FUSBa">CATE</span>, the first all-in-one living cancer therapeutic with an | + | <p>We need more specific therapies because current approaches result in many side-effects. That's why we invented <span title="Came close to being FUSBa (<yyyeaah no ;))">CATE</span>, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism. |
| − | + | ||
<p>A living cure to a living disease!</p> | <p>A living cure to a living disease!</p> | ||
<br> | <br> | ||
| Line 46: | Line 45: | ||
<h1>VISION</h1> | <h1>VISION</h1> | ||
<p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors.</p> | <p>CATE consists of the non-pathogenic bacterium <span class="bacterium">E. coli</span> Nissle that has the intrinsic ability to home preferentially in tumors.</p> | ||
| − | <p>It features two | + | <p>It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.</p> |
| − | + | ||
<br> | <br> | ||
<p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Description</a></button></p> | <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Description</a></button></p> | ||
| Line 63: | Line 61: | ||
<section id="third" class="step"> | <section id="third" class="step"> | ||
<div> | <div> | ||
| − | <p>CATE is administered intravenously, travels through the blood and colonizes tumors. | + | <p>CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and |
start preparing the cytotoxic payload.</p> | start preparing the cytotoxic payload.</p> | ||
| − | <p> | + | <p> After imaging the tumor with MRI, the doctor can then activate release of the cancer-killing payload. </p> |
<br> | <br> | ||
<p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a></button></p> | <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Applied_Design" class="more">Treatment</a></button></p> | ||
| Line 87: | Line 85: | ||
<div> | <div> | ||
<p>To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules.</p> | <p>To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules.</p> | ||
| − | <p> All functions were tested and optimized to make the resulting circuit as safe and well characterized as possible.</p> | + | <p> All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.</p> |
<br> | <br> | ||
<p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Circuit" class="more">Circuit</a></button></p> | <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Circuit" class="more">Circuit</a></button></p> | ||
| Line 101: | Line 99: | ||
<br> | <br> | ||
<h1>ENGINEERING</h1> | <h1>ENGINEERING</h1> | ||
| − | <p>We increased the understanding of the | + | <p>We increased the understanding of the system's underlying mathematics by simulating the functions with models.</p><p> The models were then used to define important questions to clarify in experiments and develop efficient design strategies.</p> |
<br> | <br> | ||
<p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Dry_Lab" class="more">Dry Lab</a></button></p> | <p><button><a href="https://2017.igem.org/Team:ETH_Zurich/Dry_Lab" class="more">Dry Lab</a></button></p> | ||
</div> | </div> | ||
</section> | </section> | ||
| − | |||
| − | |||
Revision as of 09:16, 29 October 2017
WHY
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.
A living cure to a living disease!
VISION
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home preferentially in tumors.
It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.
CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and start preparing the cytotoxic payload.
After imaging the tumor with MRI, the doctor can then activate release of the cancer-killing payload.
To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules.
All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.
ENGINEERING
We increased the understanding of the system's underlying mathematics by simulating the functions with models.
The models were then used to define important questions to clarify in experiments and develop efficient design strategies.
Experimentally, we collected data to support and refine our models and to show that our system works.
ACHIEVEMENTS
We worked goal oriented and could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action.
We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.
Human Practices
We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.
Team
We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.
